Jiangsu Nhwa Pharmaceutical Co Ltd
SZSE:002262

Watchlist Manager
Jiangsu Nhwa Pharmaceutical Co Ltd Logo
Jiangsu Nhwa Pharmaceutical Co Ltd
SZSE:002262
Watchlist
Price: 22.1 CNY 0.96% Market Closed
Market Cap: 22.5B CNY
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one Jiangsu Nhwa Pharmaceutical Co Ltd stock under the Base Case scenario is 23.16 CNY. Compared to the current market price of 22.1 CNY, Jiangsu Nhwa Pharmaceutical Co Ltd is Undervalued by 5%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
23.16 CNY
Undervaluation 5%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

3.9
P/S
P/S
Price to Sales
3.9
vs History
66
vs Industry
31
Median 3Y
4.8
Median 5Y
4.4
Industry
2.4
Forward
3.2
More Details
19.6
P/E
P/E
Price to Earnings
19.6
vs History
63
vs Industry
25
Median 3Y
23
Median 5Y
21.1
Industry
20.5
Forward
15.3
More Details
24.5
P/OCF
P/OCF
Price to OCF
24.5
vs History
53
vs Industry
21
Median 3Y
25.2
Median 5Y
24.7
Industry
15.4
More Details
52.7
P/FCFE
P/FCFE
Price to FCFE
52.7
vs History
20
vs Industry
15
Median 3Y
39.2
Median 5Y
38.1
Industry
22.8
More Details
3.1
P/B
P/B
Price to Book Value
3.1
vs History
74
vs Industry
23
Median 3Y
3.8
Median 5Y
3.6
Industry
1.9
More Details
3.4
EV/S
EV/S
Enterprise Value to Sales
3.4
vs History
65
vs Industry
34
Median 3Y
4.2
Median 5Y
3.8
Industry
2.5
Forward
2.8
More Details
4.6
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.6
vs History
65
vs Industry
41
Median 3Y
5.8
Median 5Y
5.2
Industry
4.9
More Details
15.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
15.3
vs History
63
vs Industry
25
Median 3Y
18.4
Median 5Y
16.8
Industry
12.4
Forward
11.3
More Details
15.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
15.3
vs History
63
vs Industry
29
Median 3Y
18.4
Median 5Y
16.8
Industry
15.5
Forward
12
More Details
21
EV/OCF
EV/OCF
Enterprise Value to OCF
21
vs History
49
vs Industry
25
Median 3Y
21.5
Median 5Y
20.8
Industry
14
More Details
41.2
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
41.2
vs History
28
vs Industry
17
Median 3Y
35.5
Median 5Y
34.1
Industry
17.9
More Details
4.2
EV/IC
EV/IC
Enterprise Value to IC
4.2
vs History
80
vs Industry
16
Median 3Y
5.7
Median 5Y
5.4
Industry
1.8
More Details

Multiples Across Competitors

Competitors Multiples
Jiangsu Nhwa Pharmaceutical Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Jiangsu Nhwa Pharmaceutical Co Ltd
SZSE:002262
22.5B CNY 3.9 19.6 15.3 15.3
US
Eli Lilly and Co
NYSE:LLY
669.1B USD 15 64.3 36.9 40.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
356B USD 4 25.3 11.9 15.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK 6.3 18.3 11.9 13.6
CH
Roche Holding AG
SIX:ROG
193.7B CHF 3.3 16.8 9.5 11.3
CH
Novartis AG
SIX:NOVN
171.4B CHF 3.9 16.7 10.2 13.1
UK
AstraZeneca PLC
LSE:AZN
155.3B GBP 3.7 28.2 125.4 191.5
US
Merck & Co Inc
NYSE:MRK
195.2B USD 3 11.5 7.8 9.2
IE
Endo International PLC
LSE:0Y5F
162.4B USD 70 -55.5 259.5 650.8
US
Pfizer Inc
NYSE:PFE
122.1B USD 1.9 15.2 7.6 10.9
P/E Multiple
Earnings Growth PEG
CN
Jiangsu Nhwa Pharmaceutical Co Ltd
SZSE:002262
Average P/E: 24
19.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
64.3
49%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
25.3
26%
1
DK
Novo Nordisk A/S
CSE:NOVO B
18.3
19%
1
CH
Roche Holding AG
SIX:ROG
16.8
16%
1
CH
Novartis AG
SIX:NOVN
16.7
16%
1
UK
AstraZeneca PLC
LSE:AZN
28.2
36%
0.8
US
Merck & Co Inc
NYSE:MRK
11.5
18%
0.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -55.5 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.2
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Jiangsu Nhwa Pharmaceutical Co Ltd
SZSE:002262
Average EV/EBITDA: 394.8
15.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.9
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
11.9
7%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11.9
15%
0.8
CH
Roche Holding AG
SIX:ROG
9.5
8%
1.2
CH
Novartis AG
SIX:NOVN
10.2
5%
2
UK
AstraZeneca PLC
LSE:AZN
125.4
9%
13.9
US
Merck & Co Inc
NYSE:MRK
7.8
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
259.5
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
3%
2.5
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Jiangsu Nhwa Pharmaceutical Co Ltd
SZSE:002262
Average EV/EBIT: 1 697.7
15.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
40.7
33%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
15.6
12%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
13.6
16%
0.8
CH
Roche Holding AG
SIX:ROG
11.3
9%
1.3
CH
Novartis AG
SIX:NOVN
13.1
8%
1.6
UK
AstraZeneca PLC
LSE:AZN
191.5
21%
9.1
US
Merck & Co Inc
NYSE:MRK
9.2
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
650.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.9
10%
1.1

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 245,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.